Albert David
NSE: ALBERTDAVD · Pharmaceuticals
Snapshot
Unlock Albert David's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Albert David Limited is an Indian pharmaceutical company engaged in the manufacturing and trading of formulations, infusion solutions, herbal products, and medical disposables. The company operates across diverse therapeutic segments including parenterals, topical agents, and vision care.
Business Model
The company generates revenue through the production and sale of pharmaceutical formulations and medical devices, catering to both domestic and international markets. It leverages a long-standing operational history since 1938 to maintain its presence in the healthcare supply chain.
- Incorporation Year:1938
Growth Outlook
Growth is driven by the expansion of its product portfolio in the parenteral and vision care segments, alongside export initiatives in Southeast Asia, Latin America, and Africa.
Key Risks
- Regulatory Compliance. The company faces stringent quality control and manufacturing standards imposed by domestic and international health authorities.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins.
- Currency Volatility. Exposure to international markets introduces risks related to foreign exchange fluctuations affecting export revenues.
- Supply Chain Disruptions. Dependence on the availability and cost of raw materials for bulk drugs and medical disposables poses a constant operational risk.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Albert David and 5,000+ companies — free.
Key Metrics
REVENUE
₹334 Cr
TTM · standalone
NET PROFIT
₹-1 Cr
TTM · standalone
EPS
₹-2.63
TTM · standalone
RETURN ON EQUITY
-0.4%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
0.8%
TTM · standalone
P/E
-264.0x
Q4 FY26 · standalone
EV/EBITDA
32.8x
Q4 FY26 · standalone
EBITDA MARGIN
3.9%
TTM · standalone
NET PROFIT MARGIN
-25.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Albert DavidALBERTDAVD | 371 | -263.95 | 32.85 | -3.5% | 3.9% | -0.4% | 0.8% | -24.9% |
Influx Health.INFLUX | 508 | — | — | — | 20.0% | — | — | +79.7% |
Jenburkt PharmaJENBURPH | 451 | 13.84 | 8.79 | — | 32.0% | 17.6% | 23.2% | -15.6% |
Haleos Labs LimitedHALEOSLABS | 380 | 27.58 | 12.42 | -3.2% | 14.1% | 8.9% | 12.2% | — |
Amanta HealthcarAMANTA | 377 | 36.48 | 8.39 | — | 22.0% | 6.8% | 10.0% | — |
Medicamen BiotecMEDICAMEQ | 333 | 32.99 | 14.98 | 21.7% | 11.5% | 4.3% | 6.6% | -41.1% |
As of Q4 FY26
Financials
Albert David
NSE: ALBERTDAVD · Pharmaceuticals
Snapshot
Unlock Albert David's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Albert David Limited is an Indian pharmaceutical company engaged in the manufacturing and trading of formulations, infusion solutions, herbal products, and medical disposables. The company operates across diverse therapeutic segments including parenterals, topical agents, and vision care.
Business Model
The company generates revenue through the production and sale of pharmaceutical formulations and medical devices, catering to both domestic and international markets. It leverages a long-standing operational history since 1938 to maintain its presence in the healthcare supply chain.
- Incorporation Year:1938
Growth Outlook
Growth is driven by the expansion of its product portfolio in the parenteral and vision care segments, alongside export initiatives in Southeast Asia, Latin America, and Africa.
Key Risks
- Regulatory Compliance. The company faces stringent quality control and manufacturing standards imposed by domestic and international health authorities.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins.
- Currency Volatility. Exposure to international markets introduces risks related to foreign exchange fluctuations affecting export revenues.
- Supply Chain Disruptions. Dependence on the availability and cost of raw materials for bulk drugs and medical disposables poses a constant operational risk.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Albert David and 5,000+ companies — free.
Key Metrics
REVENUE
₹334 Cr
TTM · standalone
NET PROFIT
₹-1 Cr
TTM · standalone
EPS
₹-2.63
TTM · standalone
RETURN ON EQUITY
-0.4%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
0.8%
TTM · standalone
P/E
-264.0x
Q4 FY26 · standalone
EV/EBITDA
32.8x
Q4 FY26 · standalone
EBITDA MARGIN
3.9%
TTM · standalone
NET PROFIT MARGIN
-25.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26